COMMUNIQUÉS West-GlobeNewswire

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09/01/2025 - 21:38

NAARDEN, the Netherlands and MIAMI, Jan. 09, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, [...]

Partnering to Save Lives, NMDP and the American Football Coaches Association Promote Student Athlete Philanthropy

09/01/2025 - 21:30

AFCA’s Support of NMDP Get in the Game Invites College Coaches and Student Athletes to Help Give More Patients a Second Chance at Life Through Blood Stem Cell Donations MINNEAPOLIS, Jan. 09, 2025 (GLOBE NEWSWIRE) -- [...]

IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs

09/01/2025 - 19:00

– Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited) as of December 31, 2024 – [...]

LifeLabs’ President and CEO, Charles Brown, named one of the “Top 50 Healthcare Technology CEOs of 2024”

09/01/2025 - 18:00

Toronto, Ontario, Jan. 09, 2025 (GLOBE NEWSWIRE) -- We are pleased to share that LifeLabs’ President and CEO, Charles Brown, has been named one of the “Top 50 Healthcare Technology CEOs of 2024” by The Healthcare [...]

OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference

09/01/2025 - 17:45

MIAMI, Jan. 09, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 43 r d Annual J.P. Morgan Healthcare Conference, being held January 13-16, 2025 at [...]

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment

09/01/2025 - 17:35

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment Phase 3 ABTECT Trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) reaches 1,003 of 1,224 participants, representing [...]

New Book "Prescribed Malnutrition: An Oncology Nutrition Narrative Review" Announces Critical Insights into Cancer Nutrition Misconceptions

09/01/2025 - 17:16

New book exposes cancer diet myths, debunks misconceptions about fasting, sugar, and dairy, and advocates evidence-based nutrition to support patients through oncology treatment Bucharest, Romania, Jan. 09, 2025 (GLOBE [...]

Cytosurge Announces Strategic Leadership Transition

09/01/2025 - 16:25

Simon Egli Appointed Chief Executive Officer as Co-Founder Pascal Behr Transitions to Board of Directors ZÜRICH, Switzerland, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Cytosurge AG, a leader in single-cell manipulation, a [...]

H.H.C. Group Successfully Completes URAC Monitoring Validation Review as Independent Review Organization

09/01/2025 - 16:02

ROCKVILLE, Md., Jan. 09, 2025 (GLOBE NEWSWIRE) -- H.H.C. Group (H.H.C), the leader in reducing healthcare costs by providing high-quality cost containment using claim negotiation, repricing and independent review [...]

Numab Therapeutics Announces Series C Extension to CHF 180 Million, Completing Oversubscribed CHF 50 Million Financing

09/01/2025 - 16:00

CHF 50 Million extension round co-led by Cormorant Asset Management, with participation from other existing investors Proceeds will be used to support the advancement of multiple first-in-class and best-in-class [...]

AscellaHealth Releases Q4 2024 Specialty & Rare Pipeline Digest™ Featuring Key Specialty Drug, Biosimilar, Cell and Gene Therapy Approvals

09/01/2025 - 16:00

BERWYN, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) -- AscellaHealth , a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today launched its latest Specialty & Rare Pipeline [...]

Carestream’s Focus HD Detectors, DRX-Rise Mobile X-ray System Receive European Union CE Marking Approval

09/01/2025 - 15:30

ROCHESTER, N.Y., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Carestream Health today announced today it received European Union CE Marking Approval for both its Focus HD Detectors and DRX-Rise Mobile X-ray System. “This is an [...]

CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

09/01/2025 - 15:12

BOSTON and SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Rapport Therapeutics, Inc. (Nasdaq: RAPP), please note the references to the AMPA-associated protein, [...]

BioLizard Welcomes Arjan van Manen as Commercial Director and Announces Presence at JPM Week in San Francisco

09/01/2025 - 15:00

Arjan van Manen joins BioLizard as Commercial Director, bringing over 20 years of commercial leadership experience in life sciences Meet BioLizard’s Arjan van Manen and CEO Liesbeth Ceelen at Biotech Showcase during JP [...]

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

09/01/2025 - 15:00

Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3 rd line+ setting in 2025 and expect to initiate a pivotal trial in the 2 nd line by early 2026 Presenting additional [...]

Inmagene Reports Positive Topline Results of IMG-007, a Nondepleting Anti-OX40 Monoclonal Antibody with an Extended Half-Life, for the Treatment of Atopic Dermatitis

09/01/2025 - 15:00

A 4-week treatment with IMG-007 resulted in a mean reduction in eczema area and severity index (EASI) of 77% and EASI-75 response of 54%, at week 16 Durable inhibition of inflammatory markers was observed for up to 24 [...]

Cannabix Technologies Announces Key Hardware Advancements to Marijuana Breathalyzer Technology

09/01/2025 - 14:45

VANCOUVER, British Columbia, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing [...]

FYR Appoints Chris Howlett to its Board of Directors

09/01/2025 - 14:30

Appointment adds business, market and partner development expertise to FYR board Addition highlights FYR’s evolution into partner of choice for drugmakers seeking deep insights into disease and treatment response [...]

Alkeus Pharmaceuticals Announces New Positive Interim TEASE-3 Study Results Showing Gildeuretinol Prevented Disease Progression in Early-Stage Stargardt Patients

09/01/2025 - 14:30

Two additional TEASE-3 participants who recently completed 24 months of therapy showed no disease progression, consistent with prior results. A total of five patients have completed the 24-month study. Following the [...]